Application No.: 10/526,125 3 Docket No.: 223002103000

## **Amendment to the Claims:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

## In the claims:

Claim 1 (Original) A mutant *Neisseria meningitidis* ADP-ribosylating enzyme, wherein the mutant has a substitution at one or more of amino acids Glu-109, Glu-111 or Glu-120.

Claim 2 (Original) The mutant enzyme of claim 1, wherein the mutant has reduced or eliminated ADP ribosyltransferase and/or NAD-glycohydrolase activity relative to the wild-type enzyme, wherein the wild-type enzyme has amino acid sequence SEQ ID NO: 1.

Claim 3 (Currently Amended) The mutant enzyme of claim 1 or claim 2, wherein the <u>substitution is</u> <u>Glu to Asp mutation(s) is/are preferably Glu to Asp</u>.

Claim 4 (Currently Amended) The mutant enzyme of any preceding claim 1, wherein the enzyme comprises one of the amino acid sequences SEQ ID NO: 2, SEQ ID NO: 3 or SEQ ID NO: 4.

Claim 5 (Original) A protein comprising a fragment of a *Neisseria meningitidis* ADP-ribosylating protein, wherein (i) the fragment includes one or more of amino acids Glu-109, Glu-111 or Glu-120 from said ADP-ribosylating protein, and (ii) one or more of said amino acids Glu-109, Glu-111 or Glu-120 is substituted.

Claim 6 (Currently amended) The protein of claim  $\underline{5}$  [[6]], wherein the Glu-109, Glu-111 or Glu-120 is substituted with Asp.

Claim 7 (Original) The protein of claim 6 or claim 7, wherein the fragment comprises at least 7 consecutive amino acids from the toxin or mutant toxin.

Claim 8 (Canceled).

Claim 9 (Currently Amended) The protein of <u>claim 6 in admixture with a second antigen</u> <del>any preceding claim, for use as a parenteral or mucosal vaccine adjuvant</del>.

Claim 10 (Canceled).

Claim 11 (Currently Amended) An immunogenic composition comprising the protein of any one of claim[[s]] 1 [[to 7]] in admixture with a second antigen.

Claims 12-13 (Canceled).

Claim 14 (Withdrawn-currently amended) A method of treating a patient, comprising administering a therapeutically effective amount of the protein of claims 1, 2, 4, 5, or 6 to 7 and/or the nucleic acid of claim 13 and/or the antibody of claim 12.

Claim 15 (Canceled).